0000000000133278

AUTHOR

Emmanuel Tsochatzis

0000-0001-5069-2461

showing 18 related works from this author

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct

Evaluating the association of serum ferritin and hepatic iron with disease severity in non‐alcoholic fatty liver disease

2019

Background & Aims Hyperferritinemia, with or without increased hepatic iron, represents a common finding in non‐alcoholic fatty liver disease (NAFLD). However, it is unclear whether it reflects hepatic inflammation or true iron‐overload and, in case the latter is confirmed, whether this influences disease progression. We therefore explored the association between serum ferritin, degree and pattern of hepatic iron deposition and liver disease severity in patients with NAFLD. Methods We selected 468 patients with biopsy‐proven NAFLD from 2 European centres. Iron, hepatic and metabolic parameters were collected at the time of liver biopsy. Iron deposits in hepatocytes and reticuloendothelial c…

AdultLiver CirrhosisMalemedicine.medical_specialtyIron OverloadBiopsyGastroenterologyhistology03 medical and health sciencesLiver diseaseiron0302 clinical medicineFibrosisInternal medicinemedicineHumansRetrospective StudiesMetabolic SyndromeHepatologymedicine.diagnostic_testbiologybusiness.industryferritinFatty livernon-alcoholic fatty liver diseaseMononuclear phagocyte systemMiddle Agedmedicine.diseaseFerritinLogistic ModelsLiver030220 oncology & carcinogenesisLiver biopsyFerritinsDisease Progressionbiology.proteinFemale030211 gastroenterology & hepatologyAlcoholic fatty liverferritin; histology; iron; non-alcoholic fatty liver diseaseSteatohepatitisbusinessLiver International
researchProduct

Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation

2012

Background and Aims:  Current histological scoring systems do not subclassify cirrhosis. Computer-assisted digital image analysis (DIA) of Sirius Red-stained sections measures fibrosis morphologically producing a fibrosis ratio (collagen proportionate area [CPA]). CPA could have prognostic value within a disease stage, such as cirrhosis. The aim of the present study was to evaluate CPA in patients with recurrent hepatitis C virus (HCV) allograft cirrhosis and assess its relationship with hepatic venous pressure gradient (HVPG). Methods:  In 121 consecutively-transplanted HCV patients with HVPG, measured contemporaneously with transjugular liver biopsies, 65 had Ishak stage 5 or 6 disease (4…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryPortal venous pressuremedicine.medical_treatmentGastroenterologyHepatitis CLiver transplantationmedicine.diseaseGastroenterologychemistry.chemical_compoundchemistryInterquartile rangeInternal medicinecardiovascular systemmedicinePortal hypertensionheterocyclic compoundsDecompensationbusinessSirius RedJournal of Gastroenterology and Hepatology
researchProduct

International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation.

2018

Nonalcoholic steatohepatitis (NASH)-related cirrhosis has become one of the most common indications for liver transplantation (LT), particularly in candidates older than 65 years. Typically, NASH candidates have concurrent obesity, metabolic, and cardiovascular risks, which directly impact patient evaluation and selection, waitlist morbidity and mortality, and eventually posttransplant outcomes. The purpose of these guidelines is to highlight specific features commonly observed in NASH candidates and strategies to optimize pretransplant evaluation and waitlist survival. More specifically, the working group addressed the following clinically relevant questions providing recommendations based…

Liver Cirrhosismedicine.medical_specialtyCirrhosisConsensusTime FactorsTissue and Organ ProcurementWaiting Listsmedicine.medical_treatmentConsensus Development Conferences as TopicBariatric SurgeryComorbidityLiver transplantationEnd Stage Liver DiseaseLiver diseaseNon-alcoholic Fatty Liver DiseaseDiabetes mellitusmedicineHumansObesityIntensive care medicineTransplantationbusiness.industrymedicine.diseaseComorbidityLiver TransplantationNatural historyTreatment OutcomeCardiovascular DiseasesEtiologybusinessDyslipidemiaTransplantation
researchProduct

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

2021

Summary Non-invasive tests are increasingly being used to improve the diagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis, focusing on the topics for which relevant evidence has been published in the last 5 years.

0301 basic medicinemedicine.medical_specialtyelastographyCirrhosisHepatologydecompensationbusiness.industrycirrhosisNon invasiveMEDLINENASHmedicine.diseaseClinical Practice03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicinemedicine030211 gastroenterology & hepatologyDecompensationIntensive care medicinebusinessserum markers of fibrosiscirrhosis decompensation elastography NASH serum markers of fibrosis
researchProduct

Corrigendum to ‘Baveno VII – Renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974]

2022

Porta hypertensionHepatologyJournal of Hepatology
researchProduct

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

2022

Population screening; Liver fibrosis; Early diagnosis Cribratge de població; Fibrosi hepàtica; Diagnòstic precoç Cribado de población; Fibrosis hepática; Diagnóstico precoz Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. Thes…

Liver Cirrhosismedicine.medical_specialtyCirrosi hepàtica - DiagnòsticCirrhosisFibrosiBiopsy:enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES]Population:Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES]:Otros calificadores::/diagnóstico [Otros calificadores]DiseaseFetge -- Malalties:Diagnosis::Diagnostic Techniques and Procedures::Mass Screening [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]AsymptomaticGastroenterologyGlobal Burden of DiseaseLiver diseaseHepatitis B ChronicSDG 3 - Good Health and Well-beingLiver Function TestsNon-alcoholic Fatty Liver DiseaseRisk FactorsFibrosisInternal medicinePrevalenceCribatge (Medicina):Other subheadings::/diagnosis [Other subheadings]:diagnóstico::técnicas y procedimientos diagnósticos::cribado sistemático [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]HumansMass ScreeningMedicineeducationliver fibrosiseducation.field_of_studyHepatologybusiness.industryFatty liverCirrosiHepatitis C Chronicmedicine.diseaseEarly DiagnosisLiverDisease ProgressionElasticity Imaging Techniquesmedicine.symptomTransient elastographybusinessHepatology
researchProduct

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

2021

Background: The Baveno VI consensus proposed a dual liver stiffness (LS) by transient elastography threshold of <10 and >15 kPa for excluding and diagnosing compensated advanced chronic liver disease (cACLD) in the absence of other clinical signs. Herein, we aimed to validate these criteria in a real-world multicentre study. Methods: We included 5,648 patients (mean age 51 ± 13 years, 53% males) from 10 European liver centres who had a liver biopsy and LS measurement within 6 months. We included patients with chronic hepatitis C (n = 2,913, 52%), non-alcoholic fatty liver disease (NAFLD, n = 1,073, 19%), alcohol-related liver disease (ALD, n = 946, 17%) or chronic hepatitis B (n = 716…

0301 basic medicineAlcoholic liver diseasemedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]Chronic liver diseaseAsymptomaticGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineNAFLDmedicineViral hepatitis10. No inequalityPortal hypertensionComputingMilieux_MISCELLANEOUSCirrhosiHepatologymedicine.diagnostic_testbusiness.industryFatty liverAlcoholic liver diseasemedicine.disease3. Good health030104 developmental biologyFibroscanCirrhosisLiver biopsyFIB-4030211 gastroenterology & hepatologymedicine.symptomTransient elastographybusinessViral hepatitis.
researchProduct

Baveno VII – Renewing consensus in portal hypertension

2022

To expand on the work of previous meetings, a virtual Baveno VII workshop was organised for October 2021. Among patients with compensated cirrhosis or compensated advanced chronic liver disease (cACLD – defined at the Baveno VI conference), the presence or absence of clinically significant portal hypertension (CSPH) is associated with differing outcomes, including risk of death, and different diagnostic and therapeutic needs. Accordingly, the Baveno VII workshop was entitled “Personalized Care for Portal Hypertension”. The main fields of discussion were the relevance and indications for measuring the hepatic venous pressure gradient as a gold standard, the use of non-invasive tools for the …

recommendationLiver CirrhosisCirrhosiHepatologydecompensationtreatmentdiagnosisEsophageal and Gastric VaricesPortal PressurediagnosiCirrhosisHypertension PortalrecommendationsHypertensionHumansElasticity Imaging TechniquesCirrhosis; decompensation; diagnosis; recommendations; treatmentPortalCirrhosis; decompensation; diagnosis; recommendations; treatment; Humans; Liver Cirrhosis; Portal Pressure; Elasticity Imaging Techniques; Esophageal and Gastric Varices; Hypertension Portal
researchProduct

Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patie…

2020

Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Although Milan Criteria (MC) generalized the practice of LT for HCC and improved outcomes, its predictive character has degraded with increasing candidate and oncological heterogeneity. We sought to validate and recalibrate a previously developed, preoperatively calculated, continuous risk score, the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALTHCC), in an international cohort. From 2002 to 2014, 4,089 patients (both MC in and out [25.2%]) across 16 centers in North America, Europe, and Asia were included. A continuous risk score using pre-…

OncologyMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentInternational CooperationPROGNOSTIC SCORETumor burdengastroenterologyLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCORELiver transplantationMilan criteriaRisk AssessmentLiver diseaseInternal medicinemedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapiesHEPATOCELLULAR CARCINOMARetrospective StudiesOUTCOMEFramingham Risk ScoreHepatologybusiness.industryPoorly differentiatedLiver Neoplasmshepatocelluar cancerMiddle Agedmedicine.diseasePrognosisSettore MED/18Liver TransplantationRISK FACTORSHepatocellular carcinomaCohortlocoregional therapiesFemalebusinessHepatology (Baltimore, Md.)References
researchProduct

Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 up…

2021

medicine.medical_specialtyCarcinoma HepatocellularHepatologybusiness.industryNon invasiveLiver NeoplasmsMEDLINEmedicine.diseasePrognosisSeverity of Illness IndexClinical PracticeLiver diseaseNAFLDmedicineHumansIntensive care medicinebusinessJournal of hepatology
researchProduct

Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4+CD25+FoxP3+ regulatory T cells activa…

2020

Rationale: Loss of histone macroH2A1 induces appearance of cancer stem cells (CSCs)-like cells in hepatocellular carcinoma (HCC). How CSCs interact with the tumor microenvironment and the adaptive immune system is unclear. Methods: We screened aggressive human HCC for macroH2A1 and CD44 CSC marker expression. We also knocked down (KD) macroH2A1 in HCC cells, and performed integrated transcriptomic and secretomic analyses. Results: Human HCC showed low macroH2A1 and high CD44 expression compared to control tissues. MacroH2A1 KD CSC-like cells transferred paracrinally their chemoresistant properties to parental HCC cells. MacroH2A1 KD conditioned media transcriptionally reprogrammed parental …

EXPRESSION0301 basic medicineLIVERAdaptive immune systemPOSTTRANSCRIPTIONAL CONTROLHepatocellular carcinomaMedicine (miscellaneous)PROGRESSIONHistone macroH2A1Research & Experimental MedicineCONTRIBUTES03 medical and health sciencesParacrine signalling0302 clinical medicineadaptive immune systemCancer stem cellCANCER STEM-CELLSmedicinechemoresistance.TRANSCRIPTIONIL-2 receptorneoplasmsPharmacology Toxicology and Pharmaceutics (miscellaneous)Tumor microenvironmentScience & Technologybiologyhistone macroH2A1CD44PROLIFERATIONchemoresistanceCancerFOXP3hepatocellular carcinomamedicine.diseaseAcquired immune systemdigestive system diseases3. Good healthCYTOKINE030104 developmental biologyMedicine Research & ExperimentalSENESCENCE030220 oncology & carcinogenesisCancer researchbiology.proteinLife Sciences & BiomedicineChemoresistance
researchProduct

Predictors of Re‐bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic S…

2018

Abstract Background Transjugular intrahepatic portosystemic shunt (TIPS) has proven clinical efcacy as rescue therapy for cirrhotic patients with acute portal hypertensive bleeding who fail endoscopic treatment. Aims To investigate predictive factors of 6-week and 1-year mortality in patients undergoing salvage TIPS for refractory portal hypertensive bleeding. Methods A total of 144 consecutive patients were retrospectively evaluated. Three logistic regression multivariate models were estimated to individualize prognostic factors for 6-week and 12-month mortality. Log-rank test was used to evaluate survival according to Child–Pugh classes and Bureau’s criteria. Results Mean age 51±10 years,…

AdultMalemedicine.medical_specialtyVariceal bleedingPhysiologymedicine.medical_treatmentPortal venous pressureEsophageal and Gastric VaricesLogistic regressionlaw.inventionCohort Studies03 medical and health sciences0302 clinical medicineRefractoryPredictive Value of TestsRecurrencelawInternal medicinemedicineHumansProspective StudiesMortalityRetrospective StudiesSalvage Therapybusiness.industryGastroenterologyMiddle AgedHepatologyIntensive care unitSurgeryRe bleeding030220 oncology & carcinogenesisTIPSFemale030211 gastroenterology & hepatologyPortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhagebusinessTransjugular intrahepatic portosystemic shunt
researchProduct

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.

2011

Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difficult to predict. We evaluated collagen proportionate area (CPA), a quantitative histological index, at 1 year with respect to the first episode of clinical decompensation. Patients with biopsies at 1 year after liver transplantation were evaluated by Ishak stage/grade, and biopsy samples stained with Sirius red for digital image analysis were evaluated for CPA. Cox regression was used to evaluate variables associated with first appearance of clinical decompensation. Receiver operating characteristic (ROC) curves were also used. A total of 135 patients with median follow-up of 76 months were evaluated. At 1…

Liver CirrhosisMaleCirrhosisTime FactorsPortal venous pressuremedicine.medical_treatmentBiopsyKaplan-Meier EstimateLiver transplantationmedicine.disease_causeGastroenterologyRecurrenceRisk FactorsLondonChildFirst episodemedicine.diagnostic_testMiddle AgedHepatitis CLiverFemaleCollagenAdultmedicine.medical_specialtyAdolescentHepatitis C virusHepatic VeinsRisk AssessmentSensitivity and SpecificityEnd Stage Liver DiseaseYoung AdultPredictive Value of TestsInternal medicineBiopsyImage Interpretation Computer-AssistedmedicineHumansDecompensationAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologybusiness.industrymedicine.diseaseSurgeryLiver TransplantationTransplantationROC CurveSurgerybusinessVenous PressureLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation

2013

BACKGROUND & AIMS: Histological assessment of fibrosis progression is currently performed by staging systems which are not continuous quantitative measurements. We aimed at assessing a quantitative measurement of fibrosis collagen proportionate area (CPA), to evaluate fibrosis progression and compare it to Ishak stage progression. METHODS: We studied a consecutive cohort of 155 patients with recurrent HCV hepatitis after liver transplantation (LT), who had liver biopsies at one year and were subsequently evaluated for progression of fibrosis using CPA and Ishak staging, and correlated with clinical decompensation. The upper quartile of distribution of fibrosis rates (difference in CPA or Is…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentBiopsyLiver transplantationGastroenterologySeverity of Illness IndexCohort StudiesYoung AdultFibrosisRecurrenceRisk FactorsInternal medicineSeverity of illnessBiopsyAzathioprinemedicineImage Processing Computer-AssistedHumansDecompensationAgedHepatitisHepatologymedicine.diagnostic_testliver transplantationbusiness.industryHepatitis CMiddle Agedmedicine.diseaseHepatitis CSurgeryLiverWithholding TreatmentDisease ProgressionRegression AnalysisFemaleCollagenbusinessImmunosuppressive AgentsFollow-Up Studies
researchProduct

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice.

2020

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main …

Liver Cirrhosismedicine.medical_specialtyBest practicePsychological interventionMEDLINEDiseasedigestive systemRisk Assessment03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasemedicineHumansMass ScreeningIntensive care medicinebusiness.industryPublic healthGastroenterologymedicine.diseaseAdvanced fibrosis Best practice Identification NAFLD NASHdigestive system diseasesEarly Diagnosis030220 oncology & carcinogenesisPractice Guidelines as TopicDisease Progression030211 gastroenterology & hepatologyIdentification (biology)businessAlgorithmsJournal of gastrointestinal and liver diseases : JGLD
researchProduct

The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries

2020

Environmental healthEconomic costEconomicsmedicineNon alcoholicSteatohepatitismedicine.diseaseDGVS Digital: BEST OF DGVS
researchProduct